Low tumor CD68 mRNA content (intratumoral macrophages) is predictive for benefit from adjuvant trastuzumab in HER2-positive breast cancer: An analysis of the FinHER trial

    Activity: Talk or presentationConference presentation

    Description

    Contributors: WirtZ RM, Leinonen M, Bono P, Isola J, Kellokumpu-Lehtinen PL, Kataja V, Turpeenniemi-Hujanen T, Jyrkkiö S, Eidt S, Schmidt M, Joensuu H
    Period10 Dec 2013
    Event titleBreast Cancer symposium San Antonio 2013
    Event typeOther
    Degree of RecognitionInternational